Hunan Wuhzoutong Pharmacuetical Co. Ltd.

To evaluate the use of G-CSF + plerixafor injection for stem cell mobilization before autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), and the proportion of patients achieving CD34+ cells ≥ 5×106/kg within 4 days or less compared with G-CSF + placebo.

This study was conducted to investigate the pharmacokinetic characteristics, pharmacodynamics, and preliminary safety of plerixafor injection (0.24 mg/kg) in the absorption, distribution, metabolism, and excretion of a single subcutaneous dose of G-CSF (5 μg/kg/day [Granocyte ® only]) in subjects with non-Hodgkin's lymphoma (NHL) for stem cell mobilization prior to autologous transplantation.